Resitu: minimally invasive surgical technology

Resitu biopsy device for breast lesions

Resitu's first product in development is an electrosurgical instrument intended for sampling of breast tissue during a breast biopsy procedure.

The instrument is a sterile, single-use device intended for use by radiologists and surgeons.

Large biopsies with preserved structure

The device will extract larger tissue specimens than any other instrument, including core needle biopsy and vacuum assisted biopsy needles, extracting tissues of 1 x 3 cm in size, intact with preserved structure.

Minimal tissue damage from unique combination of vacuum and electrosurgery

  • Blunt dissection reduces risks of tissue damage and bleeding during biopsy
  • Electrosurgical capability enables fine cuts and immediate coagulation

Prevention of lesion development

  • The immediate coagulation prevents further nutrition to the lesion.
  • Complete encapsulation of the lesion to prevent seeding 
  • Removal of lesion at first visit saves time and prevents further lesion growth 

Expected launch 2023

Preclinical studies are ongoing and clinical studies are planned for Q3 2022. The first instrument is expected to be CE marked and FDA cleared in 2023. Want to get more information?

Resitu

Resitu Medical AB
Rapsgatan 7B
Uppsala, Sweden

info@resitumedical.com

Resitu Medical AB is a Swedish Medical Device company founded in 2019. The company is developing instruments enabling safe removal of intact tissues by a revolutionary technology. The solution has the potential to create a paradigm shift in the management of breast cancer. The portfolio of instruments will speed up the process of cancer management using a minimally invasive approach and facilitating the way radiologists and surgeons work.

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.